{
    "info": {
        "nct_id": "NCT03515837",
        "official_title": "A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)",
        "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of Stage IV non-squamous NSCLC.\n* Documentation of tumor activating EGFR mutation, specifically either DEL19 or L858R.\n* Investigator-determined radiographic disease progression per RECIST 1.1 after treatment with an EGFR TKI therapy: a) Participants previously treated with 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have confirmed documented absence of EGFR T790M mutation; b) Participants with confirmed acquired T790M mutation after 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have osimertinib TKI treatment failure prior to enrollment; c) Participants previously failed osimertinib TKI treatment as 1st line therapy are eligible regardless of their EGFR T790M mutation status. Note: TKI washout period for all participants is 1 week or 2 half-lives after last treatment dose, whichever is longer. TKI washout should be completed prior to first dose of study treatment.\n* Measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.\n* Provided archival tumor tissue sample or newly obtained (no anti-neoplastic therapy since biopsy) core or excisional biopsy of a tumor lesion not previously irradiated.\n* Life expectancy of at least 3 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study treatment but before randomization.\n* Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after last dose of chemotherapeutic agents.\n* Female participants must not be pregnant, not breastfeeding, and must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents.\n* Adequate organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.\n* Symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.\n* Received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein-4 [CTLA-4], OX-40, CD137).\n* Received prior systemic cytotoxic chemotherapy or investigational agent(s), excluding EGFR TKIs, for metastatic NSCLC. [Notes: 1) Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC. 2) If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. 3) Prior exposure to traditional medicine(s) is allowed as long as therapy was discontinued at least 4 weeks prior to the first dose of study treatment.]\n* Received prior radiotherapy within 2 weeks of start of study treatment or has received lung radiation therapy of >30 Gray (Gy) within 6 months before the first dose of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.\n* Received a live vaccine within 30 days prior to the first dose of study treatment.\n* Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.\n* Known additional malignancy that is progressing or has required active treatment within the past 5 years. (Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.)\n* Known active untreated CNS metastases and/or carcinomatous meningitis.\n* Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.\n* Known sensitivity to any component of cisplatin, carboplatin, or pemetrexed.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Active infection requiring systemic therapy.\n* Known history of human immunodeficiency virus (HIV) infection.\n* Known history of Hepatitis B or known active Hepatitis C virus.\n* Known history of active tuberculosis (TB; Bacillus tuberculosis)\n* Pregnant, breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate organ function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provided archival tumor tissue sample or newly obtained (no anti-neoplastic therapy since biopsy) core or excisional biopsy of a tumor lesion not previously irradiated.",
            "criterions": [
                {
                    "exact_snippets": "Provided archival tumor tissue sample or newly obtained ... core or excisional biopsy of a tumor lesion",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "archival",
                                "newly obtained core biopsy",
                                "newly obtained excisional biopsy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "newly obtained (no anti-neoplastic therapy since biopsy)",
                    "criterion": "anti-neoplastic therapy since biopsy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor lesion not previously irradiated",
                    "criterion": "tumor lesion irradiation history",
                    "requirements": [
                        {
                            "requirement_type": "previous irradiation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documentation of tumor activating EGFR mutation, specifically either DEL19 or L858R.",
            "criterions": [
                {
                    "exact_snippets": "Documentation of tumor activating EGFR mutation",
                    "criterion": "tumor activating EGFR mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "specifically either DEL19 or L858R",
                    "criterion": "EGFR mutation subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "DEL19",
                                "L858R"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed diagnosis of Stage IV non-squamous NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage IV non-squamous NSCLC",
                    "criterion": "non-squamous non-small cell lung cancer (NSCLC) stage",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "non-squamous NSCLC"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST 1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Investigator-determined radiographic disease progression per RECIST 1.1 after treatment with an EGFR TKI therapy: a) Participants previously treated with 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have confirmed documented absence of EGFR T790M mutation; b) Participants with confirmed acquired T790M mutation after 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have osimertinib TKI treatment failure prior to enrollment; c) Participants previously failed osimertinib TKI treatment as 1st line therapy are eligible regardless of their EGFR T790M mutation status. Note: TKI washout period for all participants is 1 week or 2 half-lives after last treatment dose, whichever is longer. TKI washout should be completed prior to first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Investigator-determined radiographic disease progression per RECIST 1.1 after treatment with an EGFR TKI therapy",
                    "criterion": "radiographic disease progression",
                    "requirements": [
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST 1.1"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after treatment with an EGFR TKI therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants previously treated with 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have confirmed documented absence of EGFR T790M mutation",
                    "criterion": "EGFR T790M mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation_status",
                            "expected_value": "absence"
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prior_treatment",
                            "expected_value": [
                                "1st generation EGFR TKI",
                                "2nd generation EGFR TKI"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with confirmed acquired T790M mutation after 1st or 2nd generation EGFR TKI (e.g. erlotinib/afatinib/gefitinib) are required to have osimertinib TKI treatment failure prior to enrollment",
                    "criterion": "osimertinib TKI treatment failure",
                    "requirements": [
                        {
                            "requirement_type": "prior_mutation_status",
                            "expected_value": "confirmed acquired T790M mutation"
                        },
                        {
                            "requirement_type": "prior_treatment",
                            "expected_value": [
                                "1st generation EGFR TKI",
                                "2nd generation EGFR TKI"
                            ]
                        },
                        {
                            "requirement_type": "treatment_failure",
                            "expected_value": "osimertinib TKI"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants previously failed osimertinib TKI treatment as 1st line therapy are eligible regardless of their EGFR T790M mutation status",
                    "criterion": "osimertinib TKI treatment failure as 1st line therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment_failure",
                            "expected_value": "osimertinib TKI as 1st line therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "TKI washout period for all participants is 1 week or 2 half-lives after last treatment dose, whichever is longer. TKI washout should be completed prior to first dose of study treatment.",
                    "criterion": "TKI washout period",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "week"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "completion_before",
                            "expected_value": "first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after last dose of chemotherapeutic agents.",
            "criterions": [
                {
                    "exact_snippets": "Male participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after last dose of chemotherapeutic agents.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration after pembrolizumab",
                            "expected_value": {
                                "operator": ">=",
                                "value": 120,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "duration after chemotherapeutic agents",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of at least 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants must not be pregnant, not breastfeeding, and must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents.",
            "criterions": [
                {
                    "exact_snippets": "Female participants must not be pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration after pembrolizumab",
                            "expected_value": {
                                "operator": ">=",
                                "value": 120,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "duration after chemotherapeutic agents",
                            "expected_value": {
                                "operator": ">=",
                                "value": 180,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study treatment but before randomization.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study treatment",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        },
                        {
                            "requirement_type": "assessment_timeframe",
                            "expected_value": "within 7 days prior to the first dose of study treatment"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Received a live vaccine within 30 days prior to the first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Received a live vaccine within 30 days prior to the first dose of study treatment.",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)",
                    "criterion": "chronic systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily of prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 7 days prior to first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of Hepatitis B or known active Hepatitis C virus.",
            "criterions": [
                {
                    "exact_snippets": "Known history of Hepatitis B",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active Hepatitis C virus",
                    "criterion": "Hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.",
            "criterions": [
                {
                    "exact_snippets": "Predominantly squamous cell histology NSCLC",
                    "criterion": "NSCLC histology",
                    "requirements": [
                        {
                            "requirement_type": "predominant cell type",
                            "expected_value": "squamous cell"
                        }
                    ]
                },
                {
                    "exact_snippets": "if small cell elements are present, the participant is ineligible",
                    "criterion": "small cell elements in tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known additional malignancy that is progressing or has required active treatment within the past 5 years. (Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.)",
            "criterions": [
                {
                    "exact_snippets": "Known additional malignancy that is progressing or has required active treatment within the past 5 years.",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "progressing",
                                "has required active treatment within the past 5 years"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.",
                    "criterion": "history of specific malignancies (basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "potentially curative therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant, breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents",
                    "criterion": "expectation to conceive or father children during study period",
                    "requirements": [
                        {
                            "requirement_type": "expectation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "screening visit through 120 days after the last dose of pembrolizumab and up to 180 days after the last dose of chemotherapeutic agents"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.",
            "criterions": [
                {
                    "exact_snippets": "Severe hypersensitivity (≥ Grade 3) to pembrolizumab",
                    "criterion": "hypersensitivity to pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Severe hypersensitivity (≥ Grade 3) to ... any of its excipients",
                    "criterion": "hypersensitivity to pembrolizumab excipients",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Currently participating in ... a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "current participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has participated in a study of an investigational agent",
                    "criterion": "participation in a study of an investigational agent",
                    "requirements": [
                        {
                            "requirement_type": "prior participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has used an investigational device within 4 weeks prior to the first dose of study treatment",
                    "criterion": "use of an investigational device",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first dose of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active untreated CNS metastases and/or carcinomatous meningitis.",
            "criterions": [
                {
                    "exact_snippets": "Known active untreated CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "present"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received prior radiotherapy within 2 weeks of start of study treatment or has received lung radiation therapy of >30 Gray (Gy) within 6 months before the first dose of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.",
            "criterions": [
                {
                    "exact_snippets": "Received prior radiotherapy within 2 weeks of start of study treatment",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "received lung radiation therapy of >30 Gray (Gy) within 6 months before the first dose of study treatment",
                    "criterion": "lung radiation therapy dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "Gray"
                            }
                        },
                        {
                            "requirement_type": "time since lung radiation therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must have recovered from all radiation-related toxicities",
                    "criterion": "recovery from radiation-related toxicities",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not require corticosteroids",
                    "criterion": "corticosteroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not have had radiation pneumonitis",
                    "criterion": "radiation pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease",
                    "criterion": "palliative radiation to non-CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        },
                        {
                            "requirement_type": "duration of radiotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions ... is eligible.",
                    "criterion": "symptomatic ascites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "clinical stability after treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions ... is eligible.",
                    "criterion": "symptomatic pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "clinical stability after treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known sensitivity to any component of cisplatin, carboplatin, or pemetrexed.",
            "criterions": [
                {
                    "exact_snippets": "Known sensitivity to any component of cisplatin, carboplatin, or pemetrexed.",
                    "criterion": "sensitivity to components of cisplatin, carboplatin, or pemetrexed",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease that has required systemic treatment in past 2 years.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease that has required systemic treatment in past 2 years",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received prior systemic cytotoxic chemotherapy or investigational agent(s), excluding EGFR TKIs, for metastatic NSCLC. [Notes: 1) Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC. 2) If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment. 3) Prior exposure to traditional medicine(s) is allowed as long as therapy was discontinued at least 4 weeks prior to the first dose of study treatment.]",
            "criterions": [
                {
                    "exact_snippets": "Received prior systemic cytotoxic chemotherapy or investigational agent(s), excluding EGFR TKIs, for metastatic NSCLC.",
                    "criterion": "prior systemic cytotoxic chemotherapy or investigational agent(s) for metastatic NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "EGFR TKIs"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC.",
                    "criterion": "prior neoadjuvant/adjuvant chemotherapy and/or radiation",
                    "requirements": [
                        {
                            "requirement_type": "completion_time_before_diagnosis",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.",
                    "criterion": "recovery from major surgery toxicity/complications",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior exposure to traditional medicine(s) is allowed as long as therapy was discontinued at least 4 weeks prior to the first dose of study treatment.",
                    "criterion": "prior exposure to traditional medicine(s)",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation_time_before_study_treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein-4 [CTLA-4], OX-40, CD137).",
            "criterions": [
                {
                    "exact_snippets": "Received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1)",
                    "criterion": "prior therapy with anti-PD-1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Received prior therapy with an ... anti-programmed cell death-ligand 1 (anti-PD-L1)",
                    "criterion": "prior therapy with anti-PD-L1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Received prior therapy with an ... anti-PD-L2 agent",
                    "criterion": "prior therapy with anti-PD-L2 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Received prior therapy with an ... agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein-4 [CTLA-4], OX-40, CD137)",
                    "criterion": "prior therapy with agent directed to another stimulatory or co-inhibitory T-cell receptor",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of active tuberculosis (TB; Bacillus tuberculosis)",
            "criterions": [
                {
                    "exact_snippets": "Known history of active tuberculosis (TB; Bacillus tuberculosis)",
                    "criterion": "active tuberculosis history",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "History of (non-infectious) pneumonitis that required steroids",
                    "criterion": "non-infectious pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "has current pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV) infection.",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV) infection.",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}